180 related articles for article (PubMed ID: 34750805)
1. Synthetic control arms in studies of multiple myeloma and diffuse large B-cell lymphoma.
Banerjee R; Midha S; Kelkar AH; Goodman A; Prasad V; Mohyuddin GR
Br J Haematol; 2022 Mar; 196(5):1274-1277. PubMed ID: 34750805
[No Abstract] [Full Text] [Related]
2. Melflufen: A Next-Generation Nitrogen Mustard.
Holstein SA; Hillengass J; McCarthy PL
J Clin Oncol; 2021 Mar; 39(7):836-839. PubMed ID: 33439689
[No Abstract] [Full Text] [Related]
3. Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study.
Richardson PG; Bringhen S; Voorhees P; Plesner T; Mellqvist UH; Reeves B; Paba-Prada C; Zubair H; Byrne C; Chauhan D; Anderson K; Nordström E; Harmenberg J; Palumbo A; Sonneveld P
Lancet Haematol; 2020 May; 7(5):e395-e407. PubMed ID: 32213344
[TBL] [Abstract][Full Text] [Related]
4. Further progress in the treatment of multiple myeloma?
Malik PS; Kumar L
Natl Med J India; 2009; 22(1):25-7. PubMed ID: 19761157
[No Abstract] [Full Text] [Related]
5. Researchers debate best use of stem cell transplants in patients with multiple myeloma.
Rowan K
J Natl Cancer Inst; 2009 Dec; 101(23):1608-11. PubMed ID: 19910555
[No Abstract] [Full Text] [Related]
6. Melphalan hydrochloride for the treatment of multiple myeloma.
Esma F; Salvini M; Troia R; Boccadoro M; Larocca A; Pautasso C
Expert Opin Pharmacother; 2017 Aug; 18(11):1127-1136. PubMed ID: 28658983
[TBL] [Abstract][Full Text] [Related]
7. Melphalan kinetics in hyperthermic isolation perfusion of the extremities.
Loos U; Musch E; Rauschecker H; Willenbrock C
J Chemother; 1989 Jul; 1(4 Suppl):1246-7. PubMed ID: 16312851
[No Abstract] [Full Text] [Related]
8. Intracranial mass of multiple myeloma with good response to chemotherapy.
Synhaeve NE; van der Heul C; Tijssen CC
BMJ Case Rep; 2012 Sep; 2012():. PubMed ID: 23035155
[No Abstract] [Full Text] [Related]
9. OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma.
Schjesvold F; Robak P; Pour L; Aschan J; Sonneveld P
Future Oncol; 2020 Apr; 16(11):631-641. PubMed ID: 32141766
[TBL] [Abstract][Full Text] [Related]
10. Current use of monoclonal antibodies in the treatment of multiple myeloma.
Varga C; Maglio M; Ghobrial IM; Richardson PG
Br J Haematol; 2018 May; 181(4):447-459. PubMed ID: 29696629
[TBL] [Abstract][Full Text] [Related]
11. Progress in the treatment of multiple myeloma.
Kumar S
Lancet; 2006 Mar; 367(9513):791-2. PubMed ID: 16530557
[No Abstract] [Full Text] [Related]
12. Melphalan and its role in the management of patients with multiple myeloma.
Falco P; Bringhen S; Avonto I; Gay F; Morabito F; Boccadoro M; Palumbo A
Expert Rev Anticancer Ther; 2007 Jul; 7(7):945-57. PubMed ID: 17627453
[TBL] [Abstract][Full Text] [Related]
13. Multiple myeloma--translation of trial results into reality.
Moreau P; Rajkumar SV
Lancet; 2016 Jul; 388(10040):111-3. PubMed ID: 27411865
[No Abstract] [Full Text] [Related]
14. Isolated limb perfusion with melphalan for the treatment of intractable primary cutaneous diffuse large B-cell lymphoma leg type.
Kobold S; Killic N; Lütkens T; Bokemeyer C; Fiedler W
Acta Haematol; 2010; 123(3):179-81. PubMed ID: 20224270
[No Abstract] [Full Text] [Related]
15. 200 mg/m(2) melphalan--the gold standard for multiple myeloma.
Giralt S
Nat Rev Clin Oncol; 2010 Sep; 7(9):490-1. PubMed ID: 20798699
[No Abstract] [Full Text] [Related]
16. Therapeutic potential of isatuximab in the treatment of multiple myeloma: Evidence to date.
Richter J; Sanchez L; Thibaud S
Semin Oncol; 2020; 47(2-3):155-164. PubMed ID: 32446599
[TBL] [Abstract][Full Text] [Related]
17. Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE-013.
Ribrag V; Avigan DE; Green DJ; Wise-Draper T; Posada JG; Vij R; Zhu Y; Farooqui MZH; Marinello P; Siegel DS
Br J Haematol; 2019 Aug; 186(3):e41-e44. PubMed ID: 30937889
[No Abstract] [Full Text] [Related]
18. Neurological adverse events following CAR T-cell therapy: a real-world analysis.
Gajra A; Zettler ME; Phillips EG; Klink AJ; Jonathan K Kish ; Fortier S; Mehta S; Feinberg BA
Immunotherapy; 2020 Oct; 12(14):1077-1082. PubMed ID: 32808566
[No Abstract] [Full Text] [Related]
19. New developments in the treatment of patients with multiple myeloma.
Minnema MC; van der Spek E; van de Donk NW; Lokhorst HM
Neth J Med; 2010 Jan; 68(1):24-32. PubMed ID: 20103818
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo activity of melflufen (J1)in lymphoma.
Delforoush M; Strese S; Wickström M; Larsson R; Enblad G; Gullbo J
BMC Cancer; 2016 Apr; 16():263. PubMed ID: 27044263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
